LONDON, UK / ACCESSWIRE / December 16, 2019 / Midatech (MTPH.L)(MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 11 December 2019, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

Midatech Pharma announces posting of Circular convening a General Meeting Share Consolidation and ADR Ratio Change ABINGDON, OXFORDSHIRE / ACCESSWIRE / February 12, 2020 / Midatech Pharma PLC (AIM:MTPH.L) ...

Microsoft has open sourced some of its COVID-19 Threat Intelligence and is making some of its threat indicators available publicly.

While the world faces the common threat of COVID-19, defenders are working overtime to protect users all over the globe from cyber-criminals using COVID-19 as a lure to mount attacks. The post Open-sourcing new COVID-19 threat intelligence appeared first on M…

China said Sunday that relations with the United States were "on the brink of a new Cold War", fuelled in part by tensions over the coronavirus pandemic, as Muslims around the world celebrated a muted end to the holy month of Ramadan. Foreign Minister Wang Yi…

One constant for President Trump and the GOP over the last two years is how they have stayed in a competitive political landscape while flirting with disaster.

ABINGDON, OXFORDSHIRE / ACCESSWIRE / January 8, 2020 / Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce positive headline results from Study 102. The study met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration. The results demonstrate that MTD201 can deliver sustained plasma octreotide concentrations within the range needed for therapeutic efficacy with an injection interval of six to eight weeks by either subcutaneous or intramuscular administration.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 7) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) (announced ...

ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 18, 2020 / Midatech Pharma PLC ("Midatech" or the "Company") (AIM:MTPH.L; NASDAQ:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has entered into definitive binding agreements with institutional investors (the "Investors") for the purchase in a registered direct offering (the "Offering") of 1,818,182 of its American Depositary Shares ("ADSs") (each ADS representing five of the Company's ordinary shares (the "New Ordinary Shares")) at a purchase price of US$1.65 per ADS (equivalent to £0.27 per New Ordinary Share), for aggregate gross proceeds of US$3.0 million (£2.5 million). Additionally, in a concurrent private placement, the Company has agreed to issue to the Investors unregistered warrants to purchase up to an aggregate of 1,818,182 ADSs.

Hello, Friends. Happy May Day! It’s Labor Day in France today. Schools and shops would normally close today, and they are — but it feels so different this year. President Macron spoke last night and told everyone that he knows today is normally a celebratory.…

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 18, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces unaudited headline results for the year ended 31 December 2019.

Correction: The following amendment has been made to the 'UK Placing to Raise £1.8 million' announcement released on 18 May 2020. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN AND THE REPUBLIC OF SOUTH AFRICA.

LONDON, UK / ACCESSWIRE / May 12, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces that China Medical System Holdings Ltd (0867.HK) ("CMS"), its concert parties and the Company have mutually agreed to amend the relationship agreement entered into on 29 January 2019 ("Relationship Agreement"). Midatech and the CMS Concert Party have agreed to amend the Relationship Agreement to remove CMS' rights to appoint a director and observer to the Board of Midatech. The Company remains in an "Offer Period" as defined in the Takeover Code in relation to the previously announced Formal Sale Process that is underway as part of the Company's strategic review.

ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 22, 2020 / In accordance with Rule 2.9 of the Takeover Code, Midatech confirms that, as at the date of this announcement, it has 39,252,557 ordinary shares with par value £0.001 in issue ("Ordinary Shares") and admitted to trading on the AIM market of the London Stock Exchange with International Securities Identification Number GB00BKT14T00. The Company has an American Depositary Receipts facility with respect to its American Depositary Shares ("ADSs", where each ADS represents 5 Ordinary Shares) with 2,656,368 ADSs currently outstanding as of 21 May 2020, representing 13,281,840 Ordinary Shares. The ADSs are registered with the US Securities and Exchange Commission ("SEC") and are listed on The NASDAQ Capital Market with International Securities Identification Number US59564R3021.

Deep in the depths of the hydrothermal volcanic vents of the Indian Ocean lives a type of scaly-footed snail that has learned how to protect itself from the elements with iron plated armor. As Wired described back in 2015: These shells aren’t totally rigid li…

This blog wraps up the day in the life of a SOC analyst on the investigation team with insights on remediating incidents, post-incident cleanup, and impact of COVID-19 on the SOC. This is the sixth blog post in the series. The post Lessons learned from the M…

ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 21, 2020 / In accordance with Rule 2.9 of the Takeover Code, Midatech confirms that, as at the date of this announcement, it has 32,585,891 ordinary shares with par value £0.001 in issue ("Ordinary Shares") and admitted to trading on the AIM market of the London Stock Exchange with International Securities Identification Number GB00BKT14T00. The Company has an American Depositary Receipts facility with respect to its American Depositary Shares ("ADSs", where each ADS represents 5 Ordinary Shares) with 2,711,368 ADSs currently outstanding as of 20 May 2020, representing 13,556,840 Ordinary Shares. The ADSs are registered with the US Securities and Exchange Commission ("SEC") and are listed on The NASDAQ Capital Market with International Securities Identification Number US59564R3021.

ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 1, 2020 / Midatech Pharma PLC (MTPH.L)(MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines notes the recent movement in its share price and the Company confirms that it knows of no operational or corporate reason for the share price move. As noted in the Company's recent announcements on 20 April 2020 and 31 March 2020 regarding the Company's strategic review, the Company continues in its Formal Sale Process and confirms that there are no material updates following those announcements. The Company expects to announce its full year results for the year ended 31 December 2019 by the end of June 2020.

The latest round of MITRE ATT&CK evaluations proved yet again that Microsoft customers can trust they are fully protected even in the face of such an advanced attack as APT29. The post Microsoft Threat Protection leads in real-world detection in MITRE ATT&CK …

Sir John Bell, an immunologist and the Regius Chair of Medicine at the University of Oxford, said we'll probably know pretty soon whether Oxford's highly anticipated coronavirus vaccine works. Bell told NBC's Chuck Todd on Sunday's edition of Meet the Press t…

Unite the Country, a super PAC supporting Joe Biden, and the Trump campaign both launched $10 million ad campaigns this week.

ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 2, 2020 / Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has received regulatory and ethics approval to commence a further exploratory Phase I study for its MTX110 drug for diffuse midline glioma brain tumours, to be conducted at Columbia University in New York. The Columbia study will administer MTX110 via a small subcutaneously implanted pump sited in the abdominal wall, that infuses MTX110 directly to the brain tumour via tubing routed under the skin to the base of the brain. The Convection Enhanced Delivery ("CED") system is designed to facilitate chronic infusion of intracerebral chemotherapy directly into the brain.

Joe Biden’s running mate selection may be the most important in recent history, here's a look at some strength and weaknesses of some top candidates.

A new poll from Montana State University shows Democratic Gov. Steve Bullock leading incumbent GOP Sen. Steve Daines, and Joe Biden inching toward President Trump's lead.

ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 21, 2020 / Midatech Pharma PLC (MTPH.L)(MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, today announced the closing of its previously announced registered direct offering (the "Offering") of 1,818,182 of its American Depositary Shares ("ADSs") (each ADS representing five of the Company's ordinary shares (the "New Ordinary Shares")) at a purchase price of US$1.65 per ADS (equivalent to £0.27 per New Ordinary Share). Additionally, in a concurrent private placement, the Company issued to the investors unregistered warrants to purchase up to 1,818,182 ADSs ("Warrant ADSs"). The net proceeds to Midatech from the offering are expected to be approximately US$2.6 million (£2.1 million), after deducting the placement agent's fees and other estimated offering expenses.

LONDON / ACCESSWIRE / March 31, 2020 / Midatech Pharma PLC (MTPH.L)(MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients announces that, in view of prevailing conditions in the capital markets and the prospects for raising additional funds and partnering of assets, the Board of Midatech is in the process of implementing a strategic review of its operations. The Company believes the remaining costs to complete the Phase III clinical programme of MTD201 (octreotide sustained release) and manufacturing scale-up at its Bilbao facility are of the order of $30 million. The Board has concluded, in the context of its current cash runway, that the Company is unlikely to conclude a license transaction or raise sufficient funds to continue the required remaining investment in MTD201 on a timely basis.

White House Advisor Peter Navarro said the CDC "really let the country down"

For the last couple of months, cybercriminals have taken advantage of the coronavirus pandemic to launch a series of attacks on individuals and companies, with a COVID-19 angle. In order to fight these threats, Microsoft has open-sourced its threat knowledge …

The Poynter Report is our daily media newsletter. To have it delivered to your inbox Monday-Friday, click here. When Larry Hobbs first heard about the shooting, he thought something sounded wrong. “It didn’t smell good from the start,” Hobbs told me. “And it …

As some states in the U.S. begin to re-open parts of their economies, scientists are anticipating a growth in coronavirus cases in those areas in the next few weeks.The University of Washington's Institute for Health Metrics and Evaluation Director Christophe…

ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 22, 2020 / Midatech Pharma PLC (MTP)(MTPH.L) The following amendment has been made to Midatech's 2.9 announcement that was released on the 20 April 2020 which had the incorrect International Securities Identification Number ("ISIN") for the Company's American Depositary Receipts ("ADRs"). The ISIN for these ADRs is US59564R3021. In accordance with Rule 2.9 of the Takeover Code, Midatech confirms that, as at the date of this announcement, it has 23,494,981 ordinary shares with par value £0.001 in issue ("Ordinary Shares") and admitted to trading on the AIM market of the London Stock Exchange with International Securities Identification Number GB00BKT14T00.

Treasury Secretary Steven Mnuchin warned of “permanent economic damage” if states don’t reopen.

ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 2, 2020 / Midatech Pharma PLC (AIM:MTPH.L; NASDAQ:MTP) ("Midatech" or the "Company"), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces that all resolutions were passed at a general meeting of shareholders of the Company held earlier today. Consequently, with effect from tomorrow, 3 March 2020, Midatech's existing ordinary shares of 0.005p each in the capital of the Company ("Existing Ordinary Shares") will be consolidated on a one for 20 basis into new ordinary shares of 0.1p each in the capital of the Company ("New Ordinary Shares").

The Poynter Report is our daily media newsletter. To have it delivered to your inbox Monday-Friday, click here. “Meet the Press” made a big mistake on Sunday. They made a big apology on Tuesday. During Sunday’s show, moderator Chuck Todd set up a panel discus…

President Trump new coronavirus TV ad hits critics like Joe Biden and Nancy Pelosi, argues America writing the 'the greatest comeback story'

THIS IS AN ANNOUNCEMENT UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "TAKEOVER CODE") AND IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE TAKEOVER CODE. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN EU REGULATION NO. 596/2014 AND IS IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 7 OF THAT REGULATION.

THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN AND THE REPUBLIC OF SOUTH AFRICA. Upon the closing of the UK Placing and U.S. Registered Direct Offering, the Company will have raised gross proceeds of £4.3 million (using a GBP:USD exchange rate of 1.2199) ("Combined Proceeds").

LONDON, UK / ACCESSWIRE / December 5, 2019 / Midatech Pharma PLC ("Midatech" or the "Company") (AIM:MTPH.L; Nasdaq:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has received confirmation of a €2.6 million EU grant to be used to conduct a ground-breaking clinical study, GlioKIDS, designed to demonstrate the efficacy of MTX110 as a treatment for Diffuse Intrinsic Pontine Glioma ("DIPG"), a rare and fatal form of childhood brain cancer with an average life expectancy of 7 to 9 months. The grant is under the EU EIC Accelerator SME Instrument and is part of the European Innovation Council ("EIC") that supports top class innovators and small companies with funding opportunities to establish market-creating innovations that shape new markets and generate jobs, growth and higher standards of living.

Despite great progress in the synthesis of aluminosilicate zeolites, there are still a large number of zeolites that could not be prepared in the aluminosilicate form. One of typical examples is ITH zeolite, where direct synthesis of aluminosilicate ITH is cu…